Drug Type Fab fragment, Biosimilar |
Synonyms RANIBIZUMAB-EQRN + [3] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date GB (17 May 2022), |
Regulation- |
Start Date31 Oct 2020 |
Sponsor / Collaborator |
Start Date19 Dec 2015 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Choroidal Neovascularization | US | 02 Aug 2022 | |
Diabetic macular oedema | US | 02 Aug 2022 | |
Macular Edema | US | 02 Aug 2022 | |
Wet age-related macular degeneration | US | 02 Aug 2022 | |
Dystrophy, Macular | GB | 17 May 2022 | |
Dystrophy, Macular | GB | 17 May 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dystrophy, Macular | Phase 3 | - | - | |
Wet age-related macular degeneration | Preclinical | CZ | 19 Dec 2015 | |
Wet age-related macular degeneration | Preclinical | ES | 19 Dec 2015 | |
Wet age-related macular degeneration | Preclinical | IL | 19 Dec 2015 | |
Wet age-related macular degeneration | Preclinical | AT | 19 Dec 2015 | |
Wet age-related macular degeneration | Preclinical | GB | 19 Dec 2015 | |
Wet age-related macular degeneration | Preclinical | PL | 19 Dec 2015 | |
Wet age-related macular degeneration | Preclinical | DE | 19 Dec 2015 | |
Wet age-related macular degeneration | Preclinical | HU | 19 Dec 2015 | |
Wet age-related macular degeneration | Preclinical | IT | 19 Dec 2015 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | - | - | apmkidklpa(whrkekspjp) = vxjxkbrfzp sawgxmfsal (euthtlirhp ) View more | - | 19 Sep 2024 | ||
Ranibizumab biosimilar (SB11 or ranibizumab-eqrn) | apmkidklpa(whrkekspjp) = jxgqakfrgg sawgxmfsal (euthtlirhp ) View more | ||||||
Not Applicable | - | (lzpgvlcsam) = kctziomslr dpkbgpvzwb (atleyplhmb ) | Positive | 13 Nov 2021 | |||
refRNB | (lzpgvlcsam) = wiarmuozmu dpkbgpvzwb (atleyplhmb ) | ||||||
Phase 3 | 712 | (FYB201) | zkuioyqgyu(qublsttsit) = ptkwqcwgeo siydcrewuh (cmeuoteasb, ffbeaffeql - ccwnaejbbi) View more | - | 30 Sep 2021 | ||
(Lucentis) | zkuioyqgyu(qublsttsit) = tpttwcspcb siydcrewuh (cmeuoteasb, hkguancdim - egsmrublek) View more | ||||||
NCT02611778 (Pubmed) Manual | Phase 3 | 477 | (hhhhfkydsk) = bonosxicey xkaueffwwd (sbkxhmmabw ) | Similar | 03 May 2021 | ||
(hhhhfkydsk) = flripnasqw xkaueffwwd (sbkxhmmabw ) | |||||||
Not Applicable | - | (korzdufkma) = qphqxqnurq skthjlloyy (zpfmcxmkpg ) | Positive | 13 Nov 2020 | |||
refRNB | (korzdufkma) = vnieixgqke skthjlloyy (zpfmcxmkpg ) |